Results 61 to 70 of about 48,599 (177)

All-cause mortality following a cancer diagnosis amongst multiple sclerosis patients: A Swedish population-based cohort study [PDF]

open access: yes, 2015
Background and purpose: A reduced cancer risk amongst patients with multiple sclerosis (MS) has been reported. Theoretically, this could represent a genuine reduction in risk or, alternatively, 'diagnostic neglect', where cancer is undiagnosed when ...
Bahmanyar, S.   +4 more
core   +1 more source

Comparative effectiveness of enalapril, lisinopril, and ramipril in the treatment of patients with chronic heart failure: a propensity score-matched cohort study [PDF]

open access: yes, 2017
Background: Angiotensin converting enzyme inhibitors (ACEIs) are recommended as first-line therapy in patients with heart failure with reduced ejection fraction (HFrEF). The comparative effectiveness of different ACEIs is not known. Methods and results:
Agewall, Stefan   +14 more
core   +1 more source

Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis [PDF]

open access: yes, 2019
Background More than 10 years have elapsed since human papillomavirus (HPV) vaccination was implemented. We did a systematic review and meta-analysis of the population-level impact of vaccinating girls and women against human ...
\uc9lodie, B\ue9nard   +50 more
core   +2 more sources

How “benign” is cutaneous mastocytosis? A Danish registry-based matched cohort study

open access: yesInternational Journal of Women's Dermatology, 2020
Background: There are limited estimates of the incidence rates (IRs) of mastocytosis, and only a few studies have addressed the long-term consequences of living with these diagnoses.
Line Kibsgaard, MD, PhD   +5 more
doaj   +1 more source

BRCA2 polymorphic stop codon K3326X and the risk of breast, prostate, and ovarian cancers [PDF]

open access: yes, 2016
Background: The K3326X variant in BRCA2 (BRCA2*c.9976A>T; p.Lys3326*; rs11571833) has been found to be associated with small increased risks of breast cancer.
Agnarsson, Bjarni A.   +252 more
core   +1 more source

Incidence of primary spontaneous pneumothorax: a validated, register-based nationwide study

open access: yesERJ Open Research, 2019
Objectives The incidence of primary spontaneous pneumothorax is partly unknown. Commonly quoted estimates were published decades ago and recent large-scale epidemiological publications lack validation.
Winnie Hedevang Olesen   +4 more
doaj   +1 more source

The hereditary angioedema burden of illness study in Europe (HAE-BOIS-Europe) : background and methodology [PDF]

open access: yes, 2012
Background: Hereditary angioedema (HAE) is a rare but serious disease marked by swelling attacks in the extremities, face, trunk, airway, or abdominal areas that can be spontaneous or the result of trauma and other triggers.
Aygören-Pürsün, Emel   +7 more
core   +2 more sources

Clinical risk factors and atherosclerotic plaque extent to define risk for major events in patients without obstructive coronary artery disease: the long-term coronary computed tomography angiography CONFIRM registry. [PDF]

open access: yes, 2020
AimsIn patients without obstructive coronary artery disease (CAD), we examined the prognostic value of risk factors and atherosclerotic extent.Methods and resultsPatients from the long-term CONFIRM registry without prior CAD and without obstructive (≥50%)
Achenbach, Stephan   +37 more
core   +1 more source

Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease : attrition rate and evolution of disease activity [PDF]

open access: yes, 2010
Introduction: This study is based on the results from a Belgian expanded access program in which patients with active refractory and erosive rheumatoid arthritis (RA) were treated with intravenous infusions of infliximab in combination with methotrexate.
Vander Cruyssen, Bert   +3 more
core   +1 more source

Home - About - Disclaimer - Privacy